Welcome to our dedicated page for NMDBF news (Ticker: NMDBF), a resource for investors and traders seeking the latest updates and insights on NMDBF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NMDBF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NMDBF's position in the market.
NeonMind Biosciences Inc. (OTQBC: NMDBF) has announced advancements in its lead drug candidate, NEO-001, targeted at obesity management through high-dose psilocybin treatment combined with behavioral therapy. The company plans to hold a Pre-IND meeting with the FDA and a Pre-CTA Consultation in Canada in Q4 2021, with a Phase 1/2 study expected to start in 1H2022. NEO-001 aims to improve chronic weight management by addressing psychological and behavioral deficiencies inherent in current treatments, presenting opportunities for patients with comorbid conditions such as hypertension and diabetes.
NeonMind Biosciences Inc. (CSE:NEON, OTCQB:NMDBF) has launched its NeonMind branded functional mushroom coffee products in the United States as dietary supplements. The initial release features two ground coffee SKUs, with plans to introduce two instant coffee varieties shortly. NeonMind coffees utilize adaptogens and certified organic mushroom extracts, promoting benefits such as cognitive and immune support. The product launch adheres to FDA regulations, ensuring quality and safety. The global functional mushroom market is valued at $25.4 billion, projected to grow at 8.44% CAGR through 2026.